The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Paul M. O'Byrne

Firestone Institute of Respiratory Health

Michael G DeGroote School of Medicine

McMaster University

Hamilton

Canada. Electronic address:

[email]@mcmaster.ca

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Firestone Institute of Respiratory Health, Michael G DeGroote School of Medicine, McMaster University, Hamilton, Canada. Electronic address:. 2010 - 2012
  • Department of Medicine, Mc Master University Medical Center, 1200 Main St. West, Hamilton, Canada. 2001 - 2011
  • Firestone Institute for Respiratory Health, St Joseph's Hospital, Hamilton, Canada. 2009
  • Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, St Joseph's Healthcare, Canada. 2004 - 2009

References

  1. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. O'Byrne, P.M., Rennard, S., Gerstein, H., Radner, F., Peterson, S., Lindberg, B., Carlsson, L.G., Sin, D.D. Respir. Med (2012) [Pubmed]
  2. In memoriam: Frederick E Hargreave (1938-2011). O'Byrne, P.M., Nair, P., Sterk, P.J. Thorax (2011) [Pubmed]
  3. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. O'Byrne, P.M., Pedersen, S., Carlsson, L.G., Radner, F., Thorén, A., Peterson, S., Ernst, P., Suissa, S. Am. J. Respir. Crit. Care Med. (2011) [Pubmed]
  4. Measuring asthma control: a comparison of three classification systems. O'Byrne, P.M., Reddel, H.K., Eriksson, G., Ostlund, O., Peterson, S., Sears, M.R., Jenkins, C., Humbert, M., Buhl, R., Harrison, T.W., Quirce, S., Bateman, E.D. Eur. Respir. J. (2010) [Pubmed]
  5. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma. O'Byrne, P.M., van der Linde, J., Cockcroft, D.W., Gauvreau, G.M., Brannan, J.D., Fitzgerald, M., Watson, R.M., Milot, J., Davis, B., O'Connor, M., Hart, L., Korducki, L., Hamilton, A.L., Boulet, L.P. J. Allergy Clin. Immunol. (2009) [Pubmed]
  6. Severe exacerbations and decline in lung function in asthma. O'Byrne, P.M., Pedersen, S., Lamm, C.J., Tan, W.C., Busse, W.W. Am. J. Respir. Crit. Care Med. (2009) [Pubmed]
  7. Provoked models of asthma: what have we learnt? O'Byrne, P.M., Gauvreau, G.M., Brannan, J.D. Clin. Exp. Allergy (2009) [Pubmed]
  8. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. O'Byrne, P.M., Lamm, C.J., Busse, W.W., Tan, W.C., Pedersen, S. Chest (2009) [Pubmed]
  9. Obstructive lung disease from conception to old age: differences in the treatment of adults and children with asthma. O'Byrne, P.M. Proc. Am. Thorac. Soc (2009) [Pubmed]
  10. Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma. O'Byrne, P.M., Gauvreau, G.M., Murphy, D.M. J. Allergy Clin. Immunol. (2009) [Pubmed]
  11. Phosphodiesterase-4 inhibition in COPD. O'Byrne, P.M., Gauvreau, G. Lancet (2009) [Pubmed]
  12. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. O'Byrne, P.M., Naya, I.P., Kallen, A., Postma, D.S., Barnes, P.J. Chest (2008) [Pubmed]
  13. Acute asthma intervention: insights from the STAY study. O'Byrne, P.M. J. Allergy Clin. Immunol. (2007) [Pubmed]
  14. Exacerbations of asthma and COPD: definitions, clinical manifestations and epidemiology. O'Byrne, P.M. Contrib. Microbiol (2007) [Pubmed]
  15. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. O'Byrne, P.M., Pedersen, S., Busse, W.W., Tan, W.C., Chen, Y.Z., Ohlsson, S.V., Ullman, A., Lamm, C.J., Pauwels, R.A. Chest (2006) [Pubmed]
  16. Cytokines or their antagonists for the treatment of asthma. O'Byrne, P.M. Chest (2006) [Pubmed]
  17. Pharmacological management of mild or moderate persistent asthma. O'Byrne, P.M., Parameswaran, K. Lancet (2006) [Pubmed]
  18. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. O'Byrne, P.M., Bisgaard, H., Godard, P.P., Pistolesi, M., Palmqvist, M., Zhu, Y., Ekström, T., Bateman, E.D. Am. J. Respir. Crit. Care Med. (2005) [Pubmed]
  19. Initiation, dose reduction, and duration of inhaled corticosteroid therapy. O'Byrne, P.M. Immunol. Allergy. Clin. North. Am (2005) [Pubmed]
  20. Reassessing the Th2 cytokine basis of asthma. O'Byrne, P.M., Inman, M.D., Adelroth, E. Trends Pharmacol. Sci. (2004) [Pubmed]
  21. Pharmacologic interventions to reduce the risk of asthma exacerbations. O'Byrne, P.M. Proc. Am. Thorac. Soc (2004) [Pubmed]
  22. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. O'Byrne, P.M., Barnes, P.J., Rodriguez-Roisin, R., Runnerstrom, E., Sandstrom, T., Svensson, K., Tattersfield, A. Am. J. Respir. Crit. Care Med. (2001) [Pubmed]
 
WikiGenes - Universities